H.C. Wainwright assumed coverage of Vera Therapeutics (VERA) with a Buy rating and $75 price target Vera is a clinical-stage biopharmaceutical company developing novel therapies for serious immunological diseases, the analyst tells investors in a research note. The firm says positive ORIGIN 3 topline data could pave the way for atacicept’s accelerated approval for the treatment of immunoglobulin A nephropathy. It believes the significant market potential as well as a clear regulatory pathway for accelerated approval om IgAN could potentially make Vera an acquisition target if ORIGIN 3 is successful.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue